Helperby Therapeutics

Helperby has nearly 20 years experience designing combinations of antimicrobials in order to rejuvenate old drugs and to find more uses for drugs that already exist on the market. We have developed research tools to screen for and quantify the extent of synergy occurring between different combinations of old drugs. Using this information we can identify optimally matched combinations and most of our patented combinations see 8 to 64 fold synergy in bacterial kill counts in vitro. Synergistic interactions allow us to achieve better effects with lower doses and we have a phase II trial underway with our lead product Zidistin (improves dosing regimen of colistimethate combined with Azidothymidine). More recently Helperby Therapeutics has initiated a program aimed at a cure for the new coronavirus.